Moderna shares plunged after detailed cancer vaccine trial results triggered profit-taking despite reducing melanoma recurrence risk by 42%. Investors weigh commercial prospects, regulatory timelines, and future oncology opportunities.
Moderna shares plunged after detailed cancer vaccine trial results triggered profit-taking despite reducing melanoma recurrence risk by 42%. Investors weigh commercial prospects, regulatory timelines, and future oncology opportunities.
<iframe src="https://hindustansphere.com/embed/cluster/daf9d1f19f42f28520d878e593a1af20597659a8" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Moderna Stock Selloff: Why positive cancer vaccine results failed to lift shares"></iframe>
